The NDA was submitted based on the P-III (GLORY-1) trial evaluating the safety & efficacy of Mazdutide (4 or 6mg) vs PBO in Chinese overweight or obese adults
The results depicted superior effects of Mazdutide vs PBOs in body weight change from baseline to wk32 & proportion of participants with a weight loss of ≥5% at wk32 along with the proportion with a weight loss of ≥10% or ≥15%, changes in waist circumference, systolic BP, TG, LDL-C, total cholesterol, serum uric acid & ALT. The results are expected to be presented at upcoming medical conferences in 2024
Innovent signed an exclusive license agreement with Eli Lilly for the development & potential commercialization of Mazdutide (OXM3), a GLP-1R & GCGR dual agonist
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports the Result Of Mazdutide (IBI362) in the P-II Study on Chinese Patients with Type-2 Diabetes (T2D)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
